Lilly Launches Full Range of Zepbound Doses via LillyDirect
TL;DR
Eli Lilly announced that all approved doses of Zepbound (tirzepatide) for obesity treatment will be available in single-dose vials for $499/month or less through LillyDirect's Self Pay Pharmacy Solutions, making the medication more accessible regardless of insurance, with shipments starting in early August.
Want the full story? Read the original reporting
Read on Eli Lilly and Company